Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Faculty Director, Specimen Accessioning Core
Sibley Memorial Hospital, Washington, DC.
Channing J. Paller, M.D, is Assistant Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Paller earned her M.D. at Harvard Medical School and completed her medical residency at the Johns Hopkins Hospital, where she was a member of the Osler Housestaff Program, and her Fellowship in Medical Oncology at the Johns Hopkins Kimmel Cancer Center.
As an investigator, Dr. Paller is focused on translational research and clinical trials of developmental therapeutics in prostate and other solid tumors. Her research focus is on the evaluation of new therapies, such as spindle checkpoint inhibitors and histone deacetylases inhibitors. Dr. Paller actively participates in the Johns Hopkins Kimmel Cancer Center Phase I program, with a concentration on the rigorous evaluation of natural products. She is collaborating with Genitourinary Division Director, Dr. Michael Carducci on novel clinical trials of natural products in men with rising PSA after localized therapy for prostate cancer, and was recently awarded a grant to complete an investigator-initiated Phase II clinical trial of muscadine grape skin powder in that patient population.
Dr. Paller has earned honors throughout her young career as a scientist. She was selected for both a 2011-12 Young Investigator Award by the American Society of Clinical Oncology (ASCO) and for the 2011-12 ECOG Paul Carbone Award. During her undergraduate education, she interned at the National Institutes of Health where she performed live cell microscopy. Before her work at Johns Hopkins, Dr. Paller also spent time at the Weizmann Institute in Israel’s Department of Biological Regulation, Massachusetts General Hospital’s Endocrine Unit, and McCord Hospital in South Africa, where she participated in the Harvard AIDS project.
While completing her Fellowship in oncology at Johns Hopkins Kimmel Cancer Center, Dr. Paller spent time at both the U.S. Food and Drug Administration and the National Cancer Institute’s Cancer Therapy Evaluation Program (CTEP). Her collaboration with CTEP has continued since returning to Johns Hopkins.